FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat

FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat

Submitted by admin on July 13, 2021 - 11:06am
Source: 
Seeking Alpha
News Tags: 
FibroGen
FDA
roxadustat
advisory panels
chronic kidney disease
Headline: 
FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat
snippet: 

FibroGen (FGEN -6.3%) is trading lower after the FDA posted a report on Roxadustat ahead of a decision by its advisory committee this week.

Do Not Allow Advertisers to Use My Personal information